VolitionRx (NYSE:VNRX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research report released on Wednesday. The brokerage issued a sell rating on the stock.

Separately, Cantor Fitzgerald reissued an overweight rating and issued a $2.50 price objective on shares of VolitionRx in a research report on Thursday, May 16th.

VolitionRx Stock Performance

VNRX stock opened at $0.64 on Wednesday. The stock has a 50-day simple moving average of $0.67 and a 200-day simple moving average of $0.81. The firm has a market cap of $52.77 million, a P/E ratio of -1.38 and a beta of 1.13. VolitionRx has a 1 year low of $0.55 and a 1 year high of $1.38.

VolitionRx (NYSE:VNRX) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.27 million. On average, equities research analysts predict that VolitionRx will post -0.31 EPS for the current year.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.